Search for: "TEVA USA, INC."
Results 81 - 100
of 645
Sort by Relevance
|
Sort by Date
30 Aug 2020, 10:19 am
According to DOJ’s press release: The United States has filed a False Claims Act complaint against Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. [read post]
13 Aug 2020, 9:59 pm
Teva Pharmaceuticals USA, Inc., affirmed a District Court's finding that the asserted claims to a pharmaceutical formulation were indefinite. [read post]
8 May 2020, 6:57 pm
USA,Inc., 429 F.3d 1364, 1378 (Fed. [read post]
1 Apr 2020, 3:36 pm
USA, Inc., 731 F.3d 1271, 1276 (Fed. [read post]
31 Mar 2020, 9:58 am
USA, Inc., 919 F.3d 1347 (Fed. [read post]
24 Mar 2020, 1:24 am
USA, Inc., 919 F.3d 1347 (Fed.Cir. 2019); Natural Alternatives Int'l, Inc. v. [read post]
17 Mar 2020, 1:32 pm
One Lot of Topotecan Injection 4 mg/4 mL (1 mg/mL) has been recalled by Teva Pharmaceuticals due to the presence of particulate matter. [read post]
25 Feb 2020, 2:10 am
Teva Pharmaceuticals USA, Inc., is a non-precedential decision that was issued on the briefs (without oral argument), but is worth reviewing for its discussion of anticipation and inherency in the context of method of treatment claims. [read post]
4 Feb 2020, 5:00 am
Teva Pharmaceuticals USA, Inc., the Supreme Court, in its first case addressing the AIA’s § 102, rejected this argument. [read post]
27 Jan 2020, 7:42 am
USA, Inc., 139 S. [read post]
22 Nov 2019, 2:56 pm
USA, Inc. v. [read post]
13 Nov 2019, 7:50 am
USA Inc., 919 F.3d 1347 (Fed. [read post]
30 Oct 2019, 6:31 pm
USA, Inc., 367 F.3d 1381, 1385 (Fed. [read post]
13 Aug 2019, 7:34 pm
USA, Inc. v. [read post]
19 Jun 2019, 6:18 am
Teva Pharmaceuticals USA, Inc. [read post]
6 Jun 2019, 6:49 am
Teva Pharmaceuticals USA, Inc. [read post]
5 Jun 2019, 2:37 pm
Teva Pharmaceuticals USA, Inc. [read post]
5 Jun 2019, 2:37 pm
Teva Pharmaceuticals USA, Inc. [read post]
30 May 2019, 2:02 pm
USA, Inc., 518 F.3d 1353, 1366(Fed. [read post]
21 May 2019, 6:18 am
They can be “subsumed within an already tightly circumscribed legal analysis,” as the court recently explained in the patent-construction context in Teva Pharmaceuticals USA Inc. v. [read post]
